Meanwhile, the centre on Saturday released guidelines for doctors to use investigational antiviral medication remdesivir in treating India’s Covid-19 patients, but there is still little clarity on how patients can access the drug. A day after allowing the use of antiviral drug Remdesivir and off-label application of Tocilizumab and Convalescent plasma in moderate cases of COVID-19, the Union health ministry on Sunday said the
“Use of these therapies is based on limited available evidence at present”.
The ministry clarified that Remdesivir has been included as an “investigational therapy” only for the purpose of restricted emergency use following certain news reports regarding the use of the drug as part of the clinical management protocols for COVID-19 and its availability in the country.
